Company intelligence / Profile preview

Anaxsys

Send, England, United Kingdomventureradar.com ↗

Ownership: Private
Development stage: Commercial

Overview

Anaxsys developed respiR8™, a continuous respiratory rate monitor designed to improve detection of early signs of patient deterioration. The device received CE Mark approval and was available in UK and European hospitals. A 510(k) submission was filed with the FDA for US clearance around 2012. Clinical studies supported its utility in perioperative and emergency settings, but there are no recent updates on further development or commercialization.

Therapeutic areas: OtherGastroenterology
Modalities: DeviceNon-pharmacological therapy (continuous respiratory monitoring device)
Industry: Physiological Monitoring

Partnerships

Exploristics – provided statistical/data management support for clinical development and CE mark process

Beyond the preview

Go deeper on Anaxsys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anaxsys.

Explore the full profile